Bessemer Group
URGN icon

Bessemer Group’s UroGen Pharma URGN Stock Holding History

Bessemer Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-85
Closed -$1K – 2700
2024
Q3 		$1K Buy
+85
New +$1.26K ﹤0.01% 2561
2019
Q1 		– Sell
-203
Closed -$9K – 1973
2018
Q4 		$9K Hold
203
– – ﹤0.01% 1672
2018
Q3 		$10K Buy
+203
New +$9.43K ﹤0.01% 1606

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Bessemer Group's URGN Position: Q4 2024 in Review

Bessemer Group sold out of UroGen Pharma (URGN) in Q4 2024, closing a stake of 85 shares — an estimated $1K sold.

Bessemer Group first reported a position in URGN in Q3 2018 and held it in 3 quarters. The position peaked at $10K in Q3 2018. 138 funds tracked by Wall St. Rank hold URGN as of Q4 2024.

  • Bessemer Group reported no remaining UroGen Pharma position as of Q4 2024 after selling out during the quarter.
  • Bessemer Group sold 85 UroGen Pharma shares in Q4 2024, an estimated $1K.
  • Bessemer Group first reported a position in UroGen Pharma in Q3 2018 and held it in 3 quarters.
  • Bessemer Group's UroGen Pharma position peaked at $10K in Q3 2018.
  • 138 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.